107IN - Harnessing cellular senescence for cancer prevention and therapy

Date 30 September 2012
Event ESMO Congress 2012
Session ESMO-EACR Joint symposium: Targeted therapies: Promises, successes and failures
Topics Translational Research
Presenter Pier Paolo Pandolfi
Authors P.P. Pandolfi
  • BIDMC/Harvard Medical School, 02215 - Boston/US

Abstract

We will present exciting new progress at developing what we regard as a new concept, which we refer to as “pro-senescence therapy”, that aims at utilizing cellular senescence, a built-in failsafe mechanism in mammalian cell evoked by oncogenic stress, for cancer prevention and treatment.

We will discuss how this analysis allowed us to identify novel and therapeutically relevant molecular and biological types of cellular senescence that can be evoked and potentiated pharmacologically, in turn allowing the targeting of cancer stem cells as well as the “quiescent” cancer stem cell pool for therapy.

We will analyze how these new concepts emerged from our analysis and systematic deconstruction of the molecular genetics of human cancer as studied in vivo in faithful mouse models, with particular emphasis on the role of aberrant PTEN/PI3K/AKT/mTOR signaling in tumorigenesis.

Disclosure

The author has declared no conflicts of interest.